Development of a new bombesin analog radiolabelled with lutetium-177
Carregando...
Data
2010
Data de publicação:
Orientador
Título da Revista
ISSN da Revista
Título do Volume
É parte de
É parte de
É parte de
Cellular and Molecular Biology
Exportar
Resumo
In this work we describe the first results of radiolabeling with lutetium-177 (177Lu) and in vivo biodistribution and pharmacokinetics studies in normal Balb-c mice of a new bombesin analog (BEFG2) – DOTA-Phe-X-BBN(6-14), where X is a spacer of two aminoacids. Bombesin (BBN) is an amphibian analog of human gastrin releasing peptide (GRP). Development of radiolabeled BBN derivatives as agents for diagnostic imaging and systemic radiotherapy has increased considerable because of the observation that GRP receptors (GRPr) are over-expressed in a variety of human tumor cells, such as prostate tumor cells. 177Lu-labeled peptides are attractive due to the excellent radiophysical properties and commercial availability of the radiometal. BEFG2 was successfully labeled with high yield and kept stable for more than 96 hours at 2-8º C and 1 hour in human plasma. Data analysis obtained from the in vivo studies showed that the amount of BEFG2 present in plasma decreased rapidly and became almost undetectable at 60 min p.i., indicating rapid peptide excretion, which is performed mainly by renal pathway. In addition, biodistribution and single photon emission tomography showed low abdominal accumulation of 177Lu-DOTA- Phe-X-BBN(6-14), indicating that this analog is a potential candidate for tumors target therapy.
Como referenciar
PUJATTI, P.B.; SANTOS, J.S.; MASSICANO, A.V.F.; MENGATTI, J.; ARAUJO, E.B. de. Development of a new bombesin analog radiolabelled with lutetium-177: in vivo evaluation of the biological properties in BALB-C mice. Cellular and Molecular Biology, v. 56, n. 2, p. 18-24, 2010. DOI: 10.1170/T889. Disponível em: http://repositorio.ipen.br/handle/123456789/4532. Acesso em: 20 Feb 2025.
Esta referência é gerada automaticamente de acordo com as normas do estilo IPEN/SP (ABNT NBR 6023) e recomenda-se uma verificação final e ajustes caso necessário.